CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We lower our 12-month target price by $35 to $175, based on 18.6x our 2027 EPS estimate vs its three-year historical forward P/E average of 31.7x and the peer average of 13.9x. We decrease our 2026 EPS view to $8.46 from $8.54 and our 2027 EPS to $9.40 from $9.60. We have become more cautious on EFX, though we remain positive on the new product rollout and the Vitality Index achieving 17% in Q1. The latest tri-merge note from Washington Analysis, CFRA's policy team, highlights that while GSEs confirmed "not initially" changing tri-merge requirements, FHFA exploration of single-report options creates persistent regulatory uncertainty that weighs on the stock's valuation multiple. The Iran conflict threatens to disrupt recent strong credit quality and spending trends through potential oil price shocks and economic volatility, which could suppress mortgage origination volumes. We see AI innovation as an emerging risk that could introduce longer-term structural challenges to the bureau oligopoly business model.